1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | COR L279; CORL279; LuCL4 |
| Species | Human |
| Cat.No | ABC-TC0181 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
Why choose COR-L279 from AcceGen?
AcceGen achieve unparalleled purity with negative results across bacterial, fungal, Mycoplasma (PCR), and human pathogen assessments in our rigorous sterility evaluation. Experience unwavering reliability boasting over 95% post-thaw viability, establishing a gold standard for cell line performance. Validate genetic integrity with precision through Short Tandem Repeat (STR) analysis, meticulously examining 16 probes, including 15 STR loci and Amelogenin. Witness optimal growth characteristics, duly verified by the scrutiny of morphology and immunocytochemistry utilizing multiple undifferentiation markers. Place your trust in AcceGen’s COR-L279 for the seamless integration of data and the assurance of unparalleled quality in your pharmacogenomics research endeavors.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human lung small cell carcinoma (SCLC) is a pivotal focus in scientific research, contributing significantly to various fields. Some key applications include:
Cancer Biology and Therapeutics:
Tumor Microenvironment Studies: Investigate the dynamic interactions of human lung SCLC cells with surrounding tissues, contributing insights into the tumor microenvironment.
Therapeutic Targets: Identify and explore potential therapeutic targets for the development of targeted therapies against SCLC.
Drug Discovery and Development:
Chemotherapy Studies: Utilize human lung SCLC cells to assess the efficacy and mechanisms of action of chemotherapy agents, aiding in the development of novel drugs.
Drug Resistance: Investigate drug resistance mechanisms, paving the way for the development of strategies to overcome resistance in SCLC treatment.
Molecular and Genetic Research:
Genomic Profiling: Conduct genomic studies to unravel the genetic alterations and mutations associated with human lung SCLC, contributing to a deeper understanding of its molecular landscape.
Biomarker Discovery: Identify potential biomarkers for early detection, prognosis, and monitoring of SCLC progression.
Immunotherapy Investigations:
Immune Response Studies: Explore the immune response in the context of human lung SCLC, providing insights into immunotherapeutic strategies for cancer treatment.
Checkpoint Inhibitor Research: Investigate the role of immune checkpoint inhibitors in enhancing the anti-tumor immune response in SCLC.
Cell Biology and Signaling Pathways:
Cell Cycle Regulation: Study cell cycle dysregulation in SCLC cells, contributing to the understanding of aberrant cell proliferation.
Signaling Pathway Analysis: Investigate key signaling pathways involved in SCLC pathogenesis, aiding in the development of targeted interventions.
Metastasis and Invasion Studies:
Metastatic Cascade: Examine the mechanisms underlying metastasis in human lung SCLC, providing crucial information for therapeutic strategies targeting metastatic spread.
Invasion and Migration: Study cellular invasion and migration, contributing to insights into the invasive behavior of SCLC cells.
